ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small
Go back to ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small| (NASDAQ: IBRX) | Delayed: 8.48 +0.02 (0.24%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $8.46 | 52 Week High | $ | |||
| Open | $8.46 | 52 Week Low | $ | |||
| Day High | $8.53 | P/E | N/A | |||
| Day Low | $8.20 | EPS | $ | |||
| Volume | 18,439,099 | |||||

